Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
出版年份 2021 全文链接
标题
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
作者
关键词
-
出版物
Cancers
Volume 13, Issue 6, Pages 1483
出版商
MDPI AG
发表日期
2021-03-24
DOI
10.3390/cancers13061483
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
- (2020) Rebecca Smith et al. Scientific Reports
- AR-V7 — repress to impress
- (2019) Conor A. Bradley Nature Reviews Urology
- ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
- (2019) Laura Cato et al. CANCER CELL
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
- (2019) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumor heterogeneity in prostate cancer
- (2018) Shalini S. Yadav et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
- (2018) Yiqiao Huang et al. Oncology Letters
- Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data
- (2018) Chang Wook Jeong et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells
- (2017) Maryam Ghashghaei et al. PROSTATE
- Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
- (2017) Michael L. Blute et al. PLoS One
- Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells
- (2016) Y. Wang et al. CANCER RESEARCH
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer
- (2015) Masaki Shiota et al. ENDOCRINE-RELATED CANCER
- Targeting extra-gonadal androgens in castration-resistant prostate cancer
- (2015) Emily Grist et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
- (2014) E. J. Chen et al. CLINICAL CANCER RESEARCH
- Emerging mechanisms of enzalutamide resistance in prostate cancer
- (2014) Frank Claessens et al. Nature Reviews Urology
- Small cell carcinoma of the prostate
- (2014) Rosa Nadal et al. Nature Reviews Urology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
- (2014) Mary Nakazawa et al. Hormones & Cancer
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Androgen receptor (AR) aberrations in castration-resistant prostate cancer
- (2012) Kati K. Waltering et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
- (2012) Y Li et al. ONCOGENE
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
- (2011) Changmeng Cai et al. ENDOCRINE-RELATED CANCER
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate Cancer
- (2009) C. Cai et al. CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started